# A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

> **NCT03324503** · NA · COMPLETED · sponsor: **Celgene** · enrollment: 8 (actual)

## Conditions studied

- Sarcoidosis, Pulmonary

## Interventions

- **DRUG:** Glucocorticoid (prednisone or prednisolone)

## Key facts

- **NCT ID:** NCT03324503
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2019-11-15
- **Final completion:** 2019-11-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324503, "A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03324503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*